Publication | Open Access
A novel antibody targeting TIM-3 resulting in receptor internalization for cancer immunotherapy
16
Citations
25
References
2020
Year
Our results suggest that IBI104 is a promising blocking antibody for TIM-3-mediated suppressive signaling and can serve as effective cancer immunotherapy, especially in combination with anti-PD1.
| Year | Citations | |
|---|---|---|
Page 1
Page 1